Advice
Following an abbreviated submission
calcium acetate (PhosLo) is accepted for use in NHS Scotland for prevention/treatment of hyperphosphataemia in patients with advanced renal failure on dialysis.
For patients in whom calcium acetate is an appropriate phosphate binding agent this product is available at a cost per unit of calcium equivalent to that of an existing preparation.
Download detailed advice47KB (PDF)
Medicine details
- Medicine name:
- calcium acetate (Phoslo)
- SMC ID:
- 601/10
- Indication:
- hyperphosphataemia
- Pharmaceutical company
- Fresenius Medical Care (UK) Ltd
- BNF chapter
- Nutrition and blood
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 08 February 2010